70% Pain Reduction with Fibrin Disc Repair: How a Post-Fusion Patient Achieved Mobility Without Revision Surgery
A retired engineer in his mid-60s with adjacent segment disease at L3-L4 — five years after an L4-L5 lumbar fusion — chose intra-annular fibrin injection over revision fusion and reduced pain from 7/10 to 2/10 within six months. This anonymized case study covers baseline, approach, recovery, and trade-offs.
Adjacent segment disease (ASD) is one of the most common reasons fusion patients return to a spine clinic, and it sits squarely inside the broader question of spinal fusion alternatives. Roughly 40% of back surgeries do not achieve the patient’s desired outcome, and revision surgery rates can exceed 20% within 10 years. This case shows what a non-fusion biologic path looked like for one ASD patient — the diagnostic work, the procedure logic, the recovery curve, and what the team would do differently next time.
Summary Box: At a Glance
| Element | Detail |
|---|---|
| Patient profile | Retired mechanical engineer, mid-60s, anonymized |
| History | L4-L5 fusion 5 years prior; new L3-L4 pain (adjacent segment disease) |
| Baseline VAS pain | 72 mm (severe, consistent with published fibrin cohort baseline of 72.4 mm) |
| Constraint | Wanted to avoid revision fusion; wanted to preserve L3-L4 motion |
| Approach | Intra-annular fibrin injection (biologic disc repair) at L3-L4 |
| 6-month outcome | VAS reduced to ~22 mm; functional return to light woodworking and longer walks |
| Patient-reported satisfaction | Aligned with published 70% 2-year satisfaction range for fibrin patients |
Context and Baseline
The patient came to ValorSpine after years of escalating low back pain. His original L4-L5 fusion had given him about 18–24 months of meaningful relief before pain returned, this time one level above the fused segment. By the time he was evaluated, he was rating his pain at 7/10 daily, with worsening on standing, walking, and prolonged sitting. He had stopped woodworking, shortened his daily walks, and was sleeping poorly.
Imaging confirmed advanced degenerative changes at L3-L4 with multiple annular tears and disc-height collapse. L5-S1 showed early degeneration but was not symptomatic. The pattern was a textbook presentation of adjacent segment disease: biomechanical load that previously distributed across the L4-L5 motion segment was now concentrated at L3-L4 because the fused level no longer moved.
His prior conservative care was extensive and well-documented. He had completed multiple physical therapy courses, six epidural steroid injections over two years, NSAIDs, gabapentin, chiropractic care, and acupuncture. Each modality offered short-lived relief but did not change the underlying disc pathology — consistent with the AAFP systematic review finding that epidural steroid injections are not effective for chronic low back pain alone. For a deeper read on conservative options, see our overview of non-surgical spine treatments compared.
The default surgical recommendation he received elsewhere was a revision fusion at L3-L4. That option carried a 3–6 month recovery, the same biomechanical risk of pushing degeneration up to L2-L3, and no certainty of improvement.
Expert Take: Why ASD Is the Hardest Conversation in a Spine Clinic
Patients with one fusion who develop ASD have already done everything “right” — and they’re still in pain. They are also the patients most likely to be told another fusion is the only option. The fibrin pathway is not appropriate for every ASD patient, but for those with discogenic pain confirmed by discography and intact endplates, it offers a motion-preserving alternative that traditional surgical pathways do not.
The Approach: Why Intra-Annular Fibrin Injection
The clinical team selected intra-annular fibrin injection — a biologic disc repair technique that uses a fibrin sealant to close annular tears and provide a scaffold for the disc’s natural healing response. The decision logic had four components:
- Confirmed pain generator. Provocative discography reproduced the patient’s typical pain at L3-L4 and demonstrated contrast extravasation through annular tears, identifying the disc as the source.
- Motion preservation. Fusing L3-L4 above an existing L4-L5 fusion would create a two-level rigid construct, increasing load on L2-L3 and raising the risk of a third-level ASD cascade.
- Outcome data. Published cohort data on intra-annular fibrin injection report VAS pain scores improving from 72.4 mm at baseline to 33.0 mm at 104 weeks, with 70% patient satisfaction at 2-year follow-up. For failed-back-surgery-syndrome patients specifically, 80% reported positive outcomes.
- Reversibility. If fibrin treatment failed, revision fusion remained on the table. If revision fusion failed, fibrin treatment generally did not.
The patient and his spouse were walked through the full risk profile, including the realistic timeline (healing unfolds over 6–12 months, not days) and the possibility that the procedure might not eliminate all pain. He elected to proceed. For patients earlier in this decision process, our guide on how to discuss non-surgical options with a surgeon covers the questions that lead to better-aligned recommendations.
Implementation
The procedure was performed in a single outpatient session under conscious sedation with local anesthetic. Fluoroscopic guidance was used throughout to confirm needle placement at L3-L4. A small contrast injection identified the annular tear pattern, and the fibrin sealant was then delivered into the disc and tear tracts.
Post-procedure activity was structured in three phases:
- Weeks 1–4 — Consolidation. Activity restriction (no heavy lifting, twisting, or prolonged sitting). Gentle walking encouraged. The goal was to let the fibrin polymerize and the disc environment stabilize.
- Weeks 4–12 — Reactivation. Structured physical therapy focused on core stabilization, hip mobility, and gentle lumbar mobility. Therapy was deliberately conservative around the treated segment.
- Months 3–6 — Functional return. Gradual reintroduction of personal goal activities (woodworking, longer walks, light yard work). The patient was instructed to add load slowly and to track symptom response.
Communication cadence was weekly for the first month, then monthly check-ins. The patient kept a simple pain log (0–10 daily score plus one-line activity note), which proved more useful than recall-based clinic check-ins.
Results
The recovery curve followed the pattern published cohort data predict for fibrin patients: minimal change in the first weeks, accelerating improvement from month 2 onward, and stabilization by month 6.
| Timepoint | VAS pain (mm) | 0–10 scale | Function notes |
|---|---|---|---|
| Baseline | 72 | 7/10 | Stopped woodworking; walks under 10 min |
| Week 4 | ~50 | 5/10 | Reduced sharp pain; activity restrictions still in place |
| Month 3 | ~35 | 3–4/10 | Sitting tolerance improved; walks 25–30 min |
| Month 6 | ~22 | 2/10 | Light woodworking resumed; walks 45+ min |
At the six-month follow-up, the patient reported approximately a 70% reduction in chronic low back pain compared with baseline. He had returned to woodworking in shorter sessions, increased his walking distance with his wife, and reported substantially improved sleep. He had not required revision fusion, had not restarted gabapentin, and had reduced NSAID use to occasional rather than daily.
His outcome was consistent with — not exceptional within — the published evidence base for fibrin disc treatment. That matters: this is a reproducible result, not an outlier.
What Did Not Happen
The patient’s pain did not go to zero. He still reported a 2/10 background ache after long days. He did not return to heavy lifting or unrestricted activity, and the team did not recommend that he try. The L4-L5 fusion remained in place and continued to be the dominant factor shaping his lumbar mechanics.
Lessons Learned and What We Would Do Differently
Three things stand out from this case that have shaped how the team approaches similar ASD patients:
- Earlier discography improves decision quality. The provocative discogram was the single most useful diagnostic step. In hindsight, ordering it earlier — before the patient had cycled through more steroid injections — would have shortened the time-to-treatment and reduced cumulative steroid exposure.
- Pain logs beat recall. The simple daily pain-and-activity log produced a cleaner recovery curve than monthly clinic recall. Future ASD patients are now started on the log at the consultation visit, not at the procedure visit.
- Spousal involvement matters. The patient’s wife attended every appointment. Her observations about his sitting tolerance, sleep, and mood added signal that the patient himself underweighted. Encouraging a partner or family member to attend has become a standard recommendation for ASD consultations.
One thing the team would not change: the decision to recommend fibrin over revision fusion. Given his imaging, his confirmed discogenic pain, and his goal of motion preservation, the risk-adjusted case for fibrin was strong. For patients weighing similar choices, our guide on how to evaluate spine treatment options walks through the same decision framework.
Frequently Asked Questions
What is adjacent segment disease, and how common is it after fusion?
Adjacent segment disease (ASD) is accelerated degeneration at the spinal level above or below a fused segment, caused by the redistribution of biomechanical load away from the fused level. Many fusion patients develop ASD over time, and revision surgery rates after lumbar fusion can exceed 20% within 10 years.
Is intra-annular fibrin injection an alternative to revision fusion?
For appropriately selected patients with discogenic pain and intact endplates, intra-annular fibrin injection is a motion-preserving alternative to revision fusion. Published cohort data show VAS pain scores improving from 72.4 mm at baseline to 33.0 mm at 104 weeks, with 70% patient satisfaction at 2-year follow-up.
How long is recovery from fibrin disc treatment?
The procedure itself is outpatient, but biologic healing unfolds over 6–12 months. Most patients see meaningful pain reduction by month 3 and stabilization by month 6. By contrast, recovery from spinal fusion typically takes 3–6 months or longer with greater activity restriction.
Does fibrin treatment work for failed back surgery syndrome?
Published data show that 80% of failed-back-surgery-syndrome patients report positive outcomes after intra-annular fibrin injection. The treatment is not appropriate for every post-surgical patient — selection requires confirmed discogenic pain on discography and intact disc structure on imaging.
What are the main alternatives to a second fusion?
Alternatives include intra-annular fibrin injection, PRP (where about 47% of patients achieve at least 50% pain relief at 6 months), spinal decompression therapy, and structured physical therapy with activity modification. The right choice depends on the pain generator, imaging findings, and patient goals. Our overview of the 7 best spinal fusion alternatives summarizes the options.
Sources and Further Reading
- Peer-reviewed clinical literature on intra-annular fibrin injection — VAS outcomes (72.4 mm baseline → 33.0 mm at 104 weeks), 2-year satisfaction, and failed-back-surgery-syndrome subgroup data
- Journal of Neurosurgery — surgical outcome and revision-rate data for lumbar fusion
- American Academy of Family Physicians (AAFP) — systematic review on epidural steroid injections for chronic low back pain
- National Institute of Neurological Disorders and Stroke (NINDS) — overview of low back pain prevalence and natural history
- Published cohort data on PRP for discogenic low back pain — 6-month pain-relief outcomes
Ready to Explore Your Options?
If you have already had a spinal fusion and are now facing recommendations for revision surgery, you have more options than fusion alone. Ready to explore non-surgical options for your back pain? Schedule your consultation with ValorSpine today.
